Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 84 out of 100. Biomarkers

Topic: Plasma and spinal-fluid biomarkers

Plain-language summary

A total of 18 high-quality studies comprising 24 independent datasets and 4,736 participants were included. For detecting Aβ pathology, p-tau217 measured by MS (p217_MS) demonstrated the highest diagnostic accuracy (P-score = 0.86), followed by p-tau217 ratio (p217_Ratio) (P-score = 0.78) and automated immunoassays (P-score = 0.67-0.69), all of which significantly outperformed standard p-tau181 immunoassays (P-score = 0.12). Notably, the p-tau217/Aβ 42 ratio on automated platforms provided a significant incremental AUC gain of 0.025 (95% CI: 0.005 to 0.045; I2 = 0%) compared to single-analyte assays, effectively bridging the performance gap with MS. In disease staging, while p-tau231 showed potential in detecting early amyloidosis, p-tau217_MS was superior for identifying advanced Tau-PET pathology (P-score = 0.91) and predicting MCI-to-dementia conversion (P-score = 0.82). Subgroup analyses confirmed consistent performance of p-tau217 across Han Chinese and Western cohorts, and demonstrated the diagnostic potential of serum-based assays as a viable matrix. CONCLUSIONS AND RELEVANCE: Plasma p-tau217, particularly when measured by mass spectrometry or as a ratio on fully automated platforms, offers the highest accuracy for AD diagnosis and staging. While p-tau231 may serve as an early indicator of amyloidosis, p-tau217 is the most robust marker for tau pathology and disease progression. These findings support the integration of automated p-tau217 assays into routine clinical care to streamline patient stratification for disease-modifying therapies. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier (CRD420261327845).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Chen, X., Huang, T., Shi, C., Xu, S., & Fan, S. (2026). Diagnostic performance of plasma p-Tau217, p-Tau181, and p-Tau231 across the Alzheimer's disease continuum: a network meta-analysis. Frontiers in aging neuroscience. https://doi.org/10.3389/fnagi.2026.1834591

Vancouver

Chen X, Huang T, Shi C, Xu S, Fan S. Diagnostic performance of plasma p-Tau217, p-Tau181, and p-Tau231 across the Alzheimer's disease continuum: a network meta-analysis. Frontiers in aging neuroscience. 2026. doi:10.3389/fnagi.2026.1834591. PMID: 42318558.

BibTeX

@article{chen2026-42318558,
  author  = {Chen, Xiaofen and Huang, Tingting and Shi, Chao and Xu, Shuizhi and Fan, Shuwei},
  title   = {{Diagnostic performance of plasma p-Tau217, p-Tau181, and p-Tau231 across the Alzheimer's disease continuum: a network meta-analysis}},
  journal = {Frontiers in aging neuroscience},
  year    = {2026},
  doi     = {10.3389/fnagi.2026.1834591},
  pmid    = {42318558},
  url     = {https://doi.org/10.3389/fnagi.2026.1834591}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Study details

How this study scored 84/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 2 of 2; Free to read left out, no data. 47 of the 56 points it could be judged on, which is 84 of 100. Total 84 of 100.47 of the 56 points we could judge = 84 of 100

Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 47 of the 56 points we could judge it on, which is 84 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Frontiers in aging neuroscience)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 12 / 12 A systematic review of all the studies on the question
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 3 / 4 4,736 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 42318558)
Free to read — / 2 Access not recorded — left out of this score
Points 47 / 56 Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 47 of the 56 points we could judge it on is 84 out of 100.
Total 84 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Biomarkers from nearby years

Also tagged “p-tau217”

692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →